Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $267,221.20 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the business’s stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $14.02, for a total transaction of $267,221.20. Following the transaction, the chief operating officer owned 382,132 shares in the company, valued at $5,357,490.64. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Wednesday, April 22nd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.13, for a total transaction of $269,317.80.
• On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.66, for a total transaction of $453,595.06.
• On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.55, for a total transaction of $277,323.00.
• On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.18, for a total transaction of $270,270.80.
• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total transaction of $250,639.00.
• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total transaction of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total transaction of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock opened at $14.14 on Monday. The firm has a market capitalization of $2.18 billion, a PE ratio of -35.35 and a beta of 2.29. The company’s 50-day moving average is $14.50 and its 200-day moving average is $15.99. Adaptive Biotechnologies Corporation has a fifty-two week low of $7.16 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same period in the previous year, the business earned ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ADPT. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after purchasing an additional 700 shares during the period. Bouvel Investment Partners LLC boosted its holdings in Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after purchasing an additional 904 shares during the period. California State Teachers Retirement System boosted its holdings in Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after purchasing an additional 933 shares during the period. Captrust Financial Advisors boosted its holdings in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Adaptive Biotechnologies by 3.7% in the 3rd quarter. Arizona State Retirement System now owns 31,443 shares of the company’s stock valued at $470,000 after purchasing an additional 1,120 shares during the period. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.